Year-end Sale % OFF 
Abstract
events included: IABP support (13%), renal replacement therapy (6%), infections (3.6%). No cerebrovascular events or AMI occurred. Median length of hospital stay was 5 days. At discharge, 87% patients had MR 2+. At 1 year months EF was 34.7 10.4% (p1⁄40.002 compared to baseline value). Actuarial survival at 1 year was 89.6 3%. Actuarial freedom from MR 3+ at 1 year was 79.4 4%. At 1 year, MLHFQ improved from 40 15 to 22 16 (p<0.0001). Complete QoL restoration at 1 year was achieved in 43% of the survivors. At multivariate analysis, preoperative value of serum pro-BNP 1600 pg/ml was identified as independent predictors of QoL restoration at 1 year (OR 0.2; p1⁄40.03). Conclusions: MitraClip therapy is a safe and effective therapeutic option for high-risk patients with FMR, leading to clinical and QoL improvements. Higher pro-BNP levels are associated with reduced likelihood of QoL restoration at 1 year.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
